Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty
Amelia Hummel, Alexander J. Acuña, Alexander Hornung, Ryan Lew, William Harkin, Grant E. Garrigues, Gregory Nicholson · 2026
Read Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty by Amelia Hummel, Alexander J. Acuña, Alexander Hornung, Ryan Lew, William Harkin, Grant E. Garrigues, Gregory Nicholson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675852.txt.
Description
Amelia Hummel and co-authors test a weight drug class in a 2026 study of shoulder joint swaps. The drugs were born for sugar ill and now serve weight loss on their own. Past swap reads tied them to sugar patients, not to heavy folk sans that ill.
A big claim bank let the team match heavy users sans sugar ill to like non-users. Scores were read at three months and at two years past the swap. The ask is plain: do the drugs raise or drop harm in this group. Joint teams gain a first check for a fast-growing drug class.
Catalog record
| CREATOR | Amelia Hummel, Alexander J. Acuña, Alexander Hornung, Ryan Lew, William Harkin, Grant E. Garrigues, Gregory Nicholson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |